Erenumab for headaches in idiopathic intracranial hypertension: A prospective open‐label evaluation
| Autor: | Claire Fisher, Gareth G. Lavery, Olivia Grech, Alexandra J Sinclair, Susan P Mollan, Vivek Vijay, Zerin Alimajstorovic, James L Mitchell, Julie Edwards, Andreas Yiangou |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
medicine.medical_specialty Severe headache Analgesic Research Submissions Antibodies Monoclonal Humanized 03 medical and health sciences 0302 clinical medicine Quality of life Calcitonin Gene-Related Peptide Receptor Antagonists Internal medicine Outcome Assessment Health Care Headache Disorders Secondary medicine Clinical endpoint Humans Prospective Studies 030212 general & internal medicine Papilledema Pseudotumor Cerebri business.industry calcitonin gene‐related peptide monoclonal antibody raised intracranial pressure papilledema Middle Aged medicine.disease United Kingdom Research Submission Neurology Migraine Female Neurology (clinical) medicine.symptom Open label Headaches business headache idiopathic intracranial hypertension 030217 neurology & neurosurgery Follow-Up Studies |
| Zdroj: | Headache |
| ISSN: | 1526-4610 0017-8748 |
| DOI: | 10.1111/head.14026 |
| Popis: | Objective To determine the effectiveness of erenumab in treating headaches in idiopathic intracranial hypertension (IIH) in whom papilledema had resolved. Background Disability in IIH is predominantly driven by debilitating headaches with no evidence for the use of preventative therapies. Headache therapy in IIH is an urgent unmet need. Methods A prospective, open‐label study in the United Kingdom was conducted. Adult females with confirmed diagnosis of IIH now in ocular remission (papilledema resolved) with chronic headaches (≥15 days a month) and failure of ≥3 preventative medications received erenumab 4‐weekly (assessments were 3‐monthly). The primary end point was change in monthly moderate/severe headache days (MmsHD) from baseline (30‐day pretreatment period) compared to 12 months. Results Fifty‐five patients, mean (SD) age 35.3 (9) years and mean duration of headaches 10.4 (8.4) years with 3.7 (0.9) preventative treatment failures, were enrolled. Mean baseline MmsHD was 16.1 (4.7) and total monthly headache days (MHD) was (29) 2.3. MmsHD reduced substantially at 12 months by mean (SD) [95% CI] 10.8 (4.0) [9.5, 11.9], p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text